Anand, JP; Montgomery, D. Multifunctional opioid ligands. In Handbook of Experimental Pharmacology; , Springer Berlin Heidelberg, 1 Jan 2018; . 362 kB. https://doi.org/10.1007/164_2018_104
Johnson, MW; Griffiths, RR; Hendricks, PS; Henningfield, JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 1 Jun 2018, n/a. 2.5 MB. https://doi.org/10.1016/j.neuropharm.2018.05.012 #Buprenorphine
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #10
Ellis, CR; Kruhlak, NL; Kim, MT; Hawkins, EG; Stavitskaya, L. Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking. PLOS ONE, 24 May 2018, 13 (5), e0197734. 5.5 MB. https://doi.org/10.1371/journal.pone.0197734 #Buprenorphine
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #Buprenorphine